CYChenglu Yuan

Chenglu Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chenglu Yuan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Chunyan Ji

    Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Fei Lu

    Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Fei Lu

    Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Wenhua West Road, Jinan, Shandong, 250012

    1 shared publication
  • Gege Feng

    Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, 758 Hefei Road, Qingdao, Shandong, 266035

    1 shared publication
  • Hongyuan Hao

    Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, 758 Hefei Road, Qingdao, Shandong, 266035

    1 shared publication
  • Hongyuan Hao

    Department of Hematology, Qilu Hospital of Shandong University, Qingdao, China

    1 shared publication

Latest Publications

  • SLED1 Promoting Cell Proliferation and Inhibiting Apoptosis in Acute Myeloid Leukemia: a Study

    by Jimo Jian, Nana Wang, Hongyuan Hao, Chenglu Yuan, Qian Liu, Chunyan Ji, Fei Lu

    In this study, we aimed to explore long non-coding RNA (lncRNA) sustained low-efficiency dialysis (SLED1) correlated with Bcl-2 apoptosis pathway in acute myeloid leukemia (AML). This study further aimed to determine its role in the regulation of AML progression and its action as a potential biomarker for better prognosis. AML microarray profiles GSE97485 and probe annotation from the Gene Expression Omnibus (GEO) database from the National Center for Biotechnology Information (NCBI) were detected using the GEO2R tool (http://www.ncbi.nlm.nih.gov/geo/geo2r/). The expression of AML was downloaded from the TCGA database (http://cancergenome.nih.gov/). The statistical analysis of the database was processed with R software. Bioinformatic analysis found that lncRNA SLED1 is highly expressed in AML patients and is associated with poor prognosis. We found that the increased SLED1 expression levels in AML were significantly correlated with FAB classification, human race, and age. Our study has shown that upregulation of SLED1 promoted AML cell proliferation and inhibited cell apoptosis in vitro; RNA sequencing showed increased expression of BCL-2 and indicated that SLED1 might promote the development of AML by regulating BCL-2. Our results showed that SLED1 could promote the proliferation and inhibit the apoptosis of AML cells. SLED1 might promote the development of AML by regulating BCL-2, but the mechanism involved in the progression of AML is unclear. SLED1 plays an important role in AML progression, may be applied as a rapid and economical AML prognostic indicator to predict the survival of AML patients, and help guide experiments for potential clinical drag targets.


  • Open Access

    Identification of acute myeloid leukemia-driven genes by multi-dimensional approach

    by Jimo Jian, Hongyuan Hao, Qian Liu, Wenhao Dong, Lu Li, Yalu Liu, Gege Feng, Juan Wang, Sheng Gao, Lai Chen, et al.

    Background Acute myeloid leukemia (AML), which is characterized by the uncontrolled proliferation of myeloid leukemia cells in the bone marrow and other hematopoietic tissues, and is highly heterogeneous. While with the progress of sequencing technology, understanding of the AML-related biomarkers are still incomplete. The purpose of this study is to identify potential biomarkers for diagnosis of AML. Methods Based on WGCNA analysis of gene mutation expression, methylation level distribution, mRNA expression and AML-related genes in public databases, were employed for investigating potential biomarkers for prognosis of AML. Results This study screened a total of 6,383 genes by analyzing various changes in 103 acute myeloid leukemia (AML) samples, including gene mutation expression, methylation level distribution, mRNA expression, and AML-related genes in public databases. Moreover, seven AML-related co-expression modules were mined by WGCNA analysis and twelve biomarkers associated with the AML prognosis were identified from each top 10 genes of the seven co-expression modules. The AML samples were then classified into two subgroups, the prognosis of which is significantly different, based on the expression of these twelve genes. The differentially expr essed genes are mainly involved in glucose metabolism, glutathione biosynthesis, small G protein-mediated signal transduction, and the Rap1 signaling pathway. Conclusions With the utilization of WGCNA mining, seven gene co-expression modules were identified from TCGA database and there are unreported genes that may as potential driven genes of AML and may be the direction to identify the possible molecular signatures to predict survival of AML patients and help guide experiments for potential clinical drag targets.